The estimated Net Worth of Ken Ludlum is at least $3.05 Milion dollars as of 14 August 2020. Mr. Ludlum owns over 20,000 units of Personalis Inc stock worth over $178,500 and over the last 21 years he sold PSNL stock worth over $2,716,400. In addition, he makes $152,653 as Independent Director at Personalis Inc.
Sign up
Mr. Ludlum PSNL stock SEC Form 4 insiders trading
Kenneth has made over 28 trades of the Personalis Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently he sold 20,000 units of PSNL stock worth $403,400 on 14 August 2020.
The largest trade he's ever made was buying 70,000 units of Personalis Inc stock on 24 June 2019 worth over $1,190,000. On average, Kenneth trades about 5,607 units every 112 days since 2003. As of 14 August 2020 he still owns at least 30,000 units of Personalis Inc stock.
You can see the complete history of Mr. Ludlum stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Kenneth Ludlum biography
Kenneth E. Ludlum serves as Independent Director of the Company. He has served on the board of directors of NATUS Medical, Inc., a medical device and equipment company. From February 2014 to April 2016, Mr. Ludlum served as Chief Financial Officer at CareDx, a molecular diagnostics company. Mr. Ludlum holds a B.S. in Business Administration from Lehigh University and an M.B.A. from Columbia Business School. Mr. Ludlum was selected to serve on our board of directors because of his experience working for and with healthcare, medical device, biotechnology, and diagnostic companies and his expertise in finance, accounting, and general management.
What is the salary of Kenneth Ludlum?
As the Independent Director of Personalis Inc, the total compensation of Kenneth Ludlum at Personalis Inc is $152,653. There are 13 executives at Personalis Inc getting paid more, with Aaron Tachibana having the highest compensation of $3,003,510.
How old is Kenneth Ludlum?
Kenneth Ludlum is 66, he's been the Independent Director of Personalis Inc since 2015. There are 3 older and 13 younger executives at Personalis Inc. The oldest executive at Personalis Inc is A. Blaine Bowman, 73, who is the Independent Director.
What's Kenneth Ludlum's mailing address?
Ken's mailing address filed with the SEC is 1212 TERRA BELLA AVENUE, , MOUNTAIN VIEW, CA, .
Insiders trading at Personalis Inc
Over the last 5 years, insiders at Personalis Inc have traded over $56,423,548 worth of Personalis Inc stock and bought 5,708,990 units worth $54,066,334 . The most active insiders traders include Llp Abingworth, Paul Ricci a Ai, Inc. Tempus. On average, Personalis Inc executives and independent directors trade stock every 15 days with the average trade being worth of $410,996. The most recent stock trade was executed by Ai, Inc. Tempus on 16 August 2024, trading 3,500,000 units of PSNL stock currently worth $17,745,000.
What does Personalis Inc do?
personalis is a genome-scale diagnostics company with a mission to pioneer genome guided medicine. our priority is to obtain the most accurate genetic data from each sample, and then to draw the most reliable medically-focused conclusions from these. our tests are based on whole human genome and exome sequencing, conducted in our state-of-the art laboratory. we analyze results utilizing proprietary databases, advanced human reference sequences, and sophisticated algorithms. personalis genome services provides academic, pharmaceutical, and biotech researchers an accurate and comprehensive end-to-end human genome sequencing and analysis solution. our services support researchers engaging in large case-control and family-based genome studies of complex or mendelian diseases and traits, pharmacogenomics, and cancer.
What does Personalis Inc's logo look like?
Complete history of Mr. Ludlum stock trades at Caredx Inc, IRIDEX a Personalis Inc
Personalis Inc executives and stock owners
Personalis Inc executives and other stock owners filed with the SEC include:
-
Aaron Tachibana,
Chief Financial Officer -
Clinton Musil,
Chief Business Officer -
John Stephen West,
Co-Founder, CEO, Pres & Director -
Paul Ricci,
Independent Director -
John West,
President, Chief Executive Officer, Director -
Dr. Richard Chen M.D., M.S., MS,
Sr. VP of R&D and Chief Medical Officer -
Richard Chen,
Chief Science Officer -
Aaron L. Tachibana,
Sr. VP & CFO -
Dr. Richard Chen M.S., M.D., MS,
Chief Scientific Officer -
A. Blaine Bowman,
Independent Director -
Alan Colowick,
Independent Director -
Karin Eastham,
Independent Director -
Jonathan MacQuitty,
Independent Chairman of the Board -
Kenneth Ludlum,
Independent Director -
Patrick Balthrop,
Independent Director -
Stephen Moore,
General Counsel -
Dr. Euan A. Ashley DPHIL, FRCP, M.D., Ph.D.,
Co-Founder and Member of Clinical & Scientific Advisory Board -
Prof. Russ B. Altman M.D., Ph.D.,
Co-Founder and Member of Clinical & Scientific Advisory Board -
Michael J. Fitzpatrick,
VP of Worldwide Sales -
Stephen M. Moore J.D.,
VP, Gen. Counsel & Corp. Sec. -
Carol J. Tillis,
VP of Fin. & Admin. -
Dr. Michael Snyder Ph.D.,
Co-Founder and Member of Clinical & Scientific Advisory Board -
Dr. Atul Butte,
Co-Founder and Member of Clinical & Scientific Advisory Board -
Dr. Euan A. Ashley M.D., Ph.D., FRCP, DPHIL,
Co-Founder and Member of Clinical & Scientific Advisory Board -
Prof. Russ B. Altman,
Co-Founder and Member of Clinical & Scientific Advisory Board -
Kenneth J Widder,
-
Olivia Kyusuk Bloom,
-
Ken Ludlum,
Director -
Mdv Partners, L.L.C.Mdv Ix ...,
-
Venture Partners Viii Lp Li...,
-
Venture Partners Select Iv,...,
-
Llp Abingworth,
-
Christopher M Hall,
PRESIDENT AND CEO -
Venture Partners Select Iv,...,
-
Ai, Inc. Tempus,
10% owner -
Lonnie Shoff,